Mark Sydenham

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

Christopher M. Nutting, James P. Morden, Kevin J. Harrington et al. · The Lancet Oncology · 2011 · 1.7K citations · Full text

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials

Joanne Haviland, John R. Owen, John Dewar et al. · The Lancet Oncology · 2013 · 1.4K citations · Full text

Radiation Medicine, Radiation Therapy, Breast Radiotherapy +11

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

Adrian Murray Brunt, Joanne Haviland, Duncan Wheatley et al. · The Lancet · 2020 · 1K citations · Full text

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

Charlotte E. Coles, Clare Griffin, Anna M. Kirby et al. · The Lancet · 2017 · 589 citations · Full text

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.

Stephen E. Fawell, R White, Susan Hoare et al. · Proceedings of the National Academy of Sciences · 1990 · 402 citations · Full text

Molecular Pharmacology, Breast Oncology, Antiestrogen Ici 164,384 +14